Physician profile
Reena James
NPI 1962062208
$1,316.26
in general payments reported to CMS, 2019-2025
19 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $426 · 2023: $119 · 2024: $374 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Travel and Lodging: $30.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.80 |
| Travel and Lodging | $30.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $539.44 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Esperion Therapeutics, INC. | $154.19 | 2021-2022 | |
| Gilead Sciences, INC. | $118.85 | 2024 | Biktarvy |
| Novo Nordisk INC | $83.86 | 2022-2023 | Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $80.29 | 2021-2022 | |
| Boston Scientific Corporation | $48.90 | 2022 | |
| Mannkind Corporation | $34.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.49 | 2022 | |
| Amarin Pharma, INC. | $32.65 | 2021-2022 | |
| Abbvie INC. | $28.26 | 2022 | |
| Madrigal Pharmaceuticals | $26.79 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $24.20 | 2022 | |
| Corcept Therapeutics | $20.02 | 2025 | Korlym |
| Orexo US, INC. | $19.11 | 2021 | |
| Indivior INC. | $16.75 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $15.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2021 | |
| Lilly USA, LLC | $12.82 | 2023 | Jardiance |
| Horizon Therapeutics Plc | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.